US 11,731,973 B2
Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors
Laurence Clary, La Colle sur Loup (FR); Jean-François Fournier, Antibes (FR); Gilles Ouvry, Biot (FR); Yushma Bhurruth-Alcor, Ashburn, VA (US); Etienne Thoreau, Saint Vallier de Thiey (FR); and Loïc Tomas, La-Tour-de-Peilz (CH)
Assigned to GALDERMA RESEARCH & DEVELOPMENT, Biot (FR)
Filed by GALDERMA RESEARCH & DEVELOPMENT, Biot (FR)
Filed on Jun. 19, 2020, as Appl. No. 16/907,154.
Application 16/907,154 is a continuation of application No. PCT/EP2018/086066, filed on Dec. 20, 2018.
Prior Publication US 2020/0317679 A1, Oct. 8, 2020
Int. Cl. A61K 31/519 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01); A61K 9/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 9/0014 (2013.01); C07D 519/00 (2013.01)] 17 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
A represents N;
R1 represents NH2;
R2 represents F, Cl, Br, I, or NH2;
R3 represents a fused, bicyclic heteroaryl, wherein the fused, bicyclic heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, CN, CH3, CH2CH3, CF3, NHR5, and OR6;
R4 represents C3-C10 alkyl or C3-C10 carbocyclyl;
wherein the C3-C10 alkyl is branched;
wherein the C3-C10 carbocyclyl is optionally bicyclic;
wherein the C3-C10 alkyl or C3-C10 carbocyclyl is optionally interrupted with one heteroatom selected from the group consisting of O and S; and
wherein the C3-C10 alkyl or C3-C10 carbocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of F, C3-C6 cycloalkyl, and heterocycloalkyl;
R5 represents H, C1-C6 alkyl, acyl, or cyclopropyl;
wherein the C1-C6 alkyl is saturated or unsaturated;
wherein the C1-C6 alkyl is optionally interrupted with one heteroatom selected from the group consisting of O and S; and
wherein the C1-C6 alkyl is optionally substituted with one substituent selected from the group consisting of C3-C5 cycloalkyl and heterocycloalkyl; and
R6 represents H or CH3.
 
6. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, in a physiologically acceptable medium.